deferoxamine has been researched along with Hemorrhage, Subarachnoid in 18 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to investigate hemoglobin and iron handling after subarachnoid hemorrhage (SAH), examine the relationship between iron and neuroglial cell changes, and determine whether deferoxamine (DFX) can reduce SAH-induced injury." | 7.76 | Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. ( He, Y; Hua, Y; Keep, RF; Lee, JY; Sagher, O; Xi, G, 2010) |
| " The goal of this study was to clarify the relationship between HIF-1 expression and subarachnoid hemorrhage (SAH) and to characterize the effects of deferoxamine (DFO)-induced increases in HIF-1 protein levels on the brainstem and the basilar artery (BA) after experimental SAH." | 7.74 | Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats. ( Date, I; Hishikawa, T; Ogawa, T; Ono, S; Sugiu, K; Tokunaga, K, 2008) |
| "We examined the effects of subarachnoid hemorrhage (SAH) and treatment with deferoxamine (DFO) or sympathectomy on vascular smooth muscle function, as well as the underlying mechanisms involved, by recording the responses to nor-adrenaline and serotonin in isolated carotid arteries in vitro." | 7.69 | Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage. ( Akgün, M; Göksel, M; Kaya, T; Sarioglu, Y; Solak, O; Utkan, T, 1996) |
| "The role of endothelium-related factors in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage (SAH) has gained interest since the discovery of EDRF and of endothelin-1 (ET-1)." | 7.69 | Effects of deferoxamine and sympathectomy on endothelin-1-induced contraction and acetylcholine-induced relaxation following subarachnoid hemorrhage in carotid artery. ( Akgün, M; Düzcan, E; Sarioğlu, Y; Utkan, NZ; Utkan, T, 1997) |
| "A deferoxamine-induced increase in HIF-1α/VEGF-A expression was also confirmed by western blot." | 5.72 | Activation of HIF-1α/VEGF-A pathway by deferoxamine ameliorates retinal hypoxia in a rat subarachnoid hemorrhage model. ( Deji, QZ; Deng, HJ; Gao, SQ; Han, YL; Liu, XL; Wang, X; Zhaba, WD; Zhou, ML, 2022) |
| "4." | 5.29 | The effect of deferoxamine on brain lipid peroxide levels and Na-K ATPase activity following experimental subarachnoid hemorrhage. ( Aricioğlu, A; Aykol, S; Bilgihan, A; Cevik, C; Göksel, M; Türközkan, N, 1994) |
| "Deferoxamine treatment (50 mg/kg/8 hours) was begun 16 hours before the induction of SAH and continued until the animals were killed by perfusion fixation." | 5.28 | A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. ( Hongo, K; Kassell, NF; Ogawa, H; Tsukahara, T; Vollmer, DG, 1991) |
| "The purpose of this study was to investigate hemoglobin and iron handling after subarachnoid hemorrhage (SAH), examine the relationship between iron and neuroglial cell changes, and determine whether deferoxamine (DFX) can reduce SAH-induced injury." | 3.76 | Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. ( He, Y; Hua, Y; Keep, RF; Lee, JY; Sagher, O; Xi, G, 2010) |
| " The goal of this study was to clarify the relationship between HIF-1 expression and subarachnoid hemorrhage (SAH) and to characterize the effects of deferoxamine (DFO)-induced increases in HIF-1 protein levels on the brainstem and the basilar artery (BA) after experimental SAH." | 3.74 | Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats. ( Date, I; Hishikawa, T; Ogawa, T; Ono, S; Sugiu, K; Tokunaga, K, 2008) |
| "We examined the effects of subarachnoid hemorrhage (SAH) and treatment with deferoxamine (DFO) or sympathectomy on vascular smooth muscle function, as well as the underlying mechanisms involved, by recording the responses to nor-adrenaline and serotonin in isolated carotid arteries in vitro." | 3.69 | Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage. ( Akgün, M; Göksel, M; Kaya, T; Sarioglu, Y; Solak, O; Utkan, T, 1996) |
| "The role of endothelium-related factors in the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage (SAH) has gained interest since the discovery of EDRF and of endothelin-1 (ET-1)." | 3.69 | Effects of deferoxamine and sympathectomy on endothelin-1-induced contraction and acetylcholine-induced relaxation following subarachnoid hemorrhage in carotid artery. ( Akgün, M; Düzcan, E; Sarioğlu, Y; Utkan, NZ; Utkan, T, 1997) |
| "A deferoxamine-induced increase in HIF-1α/VEGF-A expression was also confirmed by western blot." | 1.72 | Activation of HIF-1α/VEGF-A pathway by deferoxamine ameliorates retinal hypoxia in a rat subarachnoid hemorrhage model. ( Deji, QZ; Deng, HJ; Gao, SQ; Han, YL; Liu, XL; Wang, X; Zhaba, WD; Zhou, ML, 2022) |
| "Deferoxamine (DFX) has recently been shown to have a neuroprotective effect in animal models of subarachnoid haemorrhage (SAH)." | 1.40 | Possible involvement of cathepsin B/D and caspase-3 in deferoxamine-related neuroprotection of early brain injury after subarachnoid haemorrhage in rats. ( Chen, G; Jia, Y; Yu, ZQ, 2014) |
| "Aneurysmal subarachnoid hemorrhage (SAH) affects approximately 27,000 Americans per year." | 1.36 | Iron and early brain injury after subarachnoid hemorrhage. ( Loftspring, MC, 2010) |
| "With deferoxamine treatment, only a minor increase in latency periods (4." | 1.31 | Evaluation of cerebral vasospasm with transcranial magnetic stimulation: an experimental study. ( Akgün, M; Göksel, HM; Solak, O; Topaktaş, S; Topalkara, K, 2001) |
| "4." | 1.29 | The effect of deferoxamine on brain lipid peroxide levels and Na-K ATPase activity following experimental subarachnoid hemorrhage. ( Aricioğlu, A; Aykol, S; Bilgihan, A; Cevik, C; Göksel, M; Türközkan, N, 1994) |
| "Deferoxamine treatment (50 mg/kg/8 hours) was begun 16 hours before the induction of SAH and continued until the animals were killed by perfusion fixation." | 1.28 | A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage. ( Hongo, K; Kassell, NF; Ogawa, H; Tsukahara, T; Vollmer, DG, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (33.33) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 1 |
| Schwarting, J | 1 |
| Terpolilli, NA | 1 |
| Nehrkorn, K | 1 |
| Plesnila, N | 1 |
| Deji, QZ | 1 |
| Wang, X | 1 |
| Zhaba, WD | 1 |
| Deng, HJ | 1 |
| Han, YL | 1 |
| Gao, SQ | 1 |
| Liu, XL | 1 |
| Zhou, ML | 1 |
| Qin, Y | 1 |
| Li, G | 1 |
| Sun, Z | 1 |
| Xu, X | 1 |
| Gu, J | 1 |
| Gao, F | 1 |
| Yu, ZQ | 1 |
| Jia, Y | 1 |
| Chen, G | 1 |
| Egashira, Y | 1 |
| Xi, G | 3 |
| Chaudhary, N | 1 |
| Hua, Y | 3 |
| Pandey, AS | 1 |
| LeBlanc, RH | 1 |
| Chen, R | 1 |
| Selim, MH | 1 |
| Hanafy, KA | 1 |
| Li, Y | 1 |
| Yang, H | 1 |
| Ni, W | 1 |
| Gu, Y | 1 |
| Loftspring, MC | 1 |
| Lee, JY | 2 |
| Keep, RF | 2 |
| He, Y | 1 |
| Sagher, O | 1 |
| Ernestus, RI | 1 |
| Hishikawa, T | 1 |
| Ono, S | 1 |
| Ogawa, T | 1 |
| Tokunaga, K | 1 |
| Sugiu, K | 1 |
| Date, I | 1 |
| Bilgihan, A | 1 |
| Türközkan, N | 1 |
| Aricioğlu, A | 1 |
| Aykol, S | 1 |
| Cevik, C | 1 |
| Göksel, M | 2 |
| Vollrath, B | 1 |
| Chan, P | 1 |
| Findlay, M | 1 |
| Cook, D | 1 |
| Utkan, T | 2 |
| Sarioglu, Y | 2 |
| Kaya, T | 1 |
| Akgün, M | 3 |
| Solak, O | 2 |
| Düzcan, E | 1 |
| Utkan, NZ | 1 |
| Göksel, HM | 1 |
| Topalkara, K | 1 |
| Topaktaş, S | 1 |
| Harada, T | 1 |
| Mayberg, MR | 1 |
| Vollmer, DG | 1 |
| Hongo, K | 1 |
| Ogawa, H | 1 |
| Tsukahara, T | 1 |
| Kassell, NF | 1 |
18 other studies available for deferoxamine and Hemorrhage, Subarachnoid
| Article | Year |
|---|---|
Scavenging Free Iron Reduces Arteriolar Microvasospasms After Experimental Subarachnoid Hemorrhage.
Topics: Animals; Arterioles; Brain Ischemia; Capillaries; Deferoxamine; Iron; Male; Mice, Inbred C57BL; Side | 2021 |
Activation of HIF-1α/VEGF-A pathway by deferoxamine ameliorates retinal hypoxia in a rat subarachnoid hemorrhage model.
Topics: Animals; Cell Adhesion Molecules; Deferoxamine; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; | 2022 |
Comparison of the effects of nimodipine and deferoxamine on brain injury in rat with subarachnoid hemorrhage.
Topics: Animals; Atrophy; Cognitive Dysfunction; Deferoxamine; Disease Models, Animal; Ferritins; Male; Maze | 2019 |
Possible involvement of cathepsin B/D and caspase-3 in deferoxamine-related neuroprotection of early brain injury after subarachnoid haemorrhage in rats.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Injuries; Caspase 3; Cathepsin B; Cathepsin D; Defero | 2014 |
Acute Brain Injury after Subarachnoid Hemorrhage.
Topics: Acute Disease; Acute-Phase Proteins; Animals; Brain Injuries; Brain Ischemia; Deferoxamine; Hemoglob | 2015 |
Heme oxygenase-1-mediated neuroprotection in subarachnoid hemorrhage via intracerebroventricular deferoxamine.
Topics: Animals; Calcium-Binding Proteins; Cells, Cultured; Cognition Disorders; Deferoxamine; Disease Model | 2016 |
Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage.
Topics: Animals; Behavior, Animal; Blood-Brain Barrier; Brain Edema; Brain Injuries; Cognition; Deferoxamine | 2017 |
Iron and early brain injury after subarachnoid hemorrhage.
Topics: Animals; Brain Diseases; Deferoxamine; DNA Damage; Humans; Iron; Iron Chelating Agents; Oxidative St | 2010 |
Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury.
Topics: Animals; Blotting, Western; Brain; Cell Death; Deferoxamine; DNA Damage; Heme Oxygenase-1; Hemoglobi | 2010 |
Deferoxamine reduces early brain injury following subarachnoid hemorrhage.
Topics: Analysis of Variance; Animals; Brain; Brain Injuries; Deferoxamine; Disease Models, Animal; DNA Dama | 2011 |
Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats.
Topics: Animals; Brain Stem; Cerebrovascular Circulation; Deferoxamine; Disease Models, Animal; Electrophore | 2008 |
The effect of deferoxamine on brain lipid peroxide levels and Na-K ATPase activity following experimental subarachnoid hemorrhage.
Topics: Animals; Brain; Deferoxamine; Disease Models, Animal; Female; Guinea Pigs; Lipid Peroxides; Male; So | 1994 |
Lazaroids and deferoxamine attenuate the intracellular effects of oxyhaemoglobin in vascular smooth muscle.
Topics: Animals; Antioxidants; Calcium; Cell Line; Cell Survival; Chelating Agents; Chromans; Deferoxamine; | 1995 |
Effect of deferoxamine and sympathectomy on vasospasm following subarachnoid hemorrhage.
Topics: Animals; Carotid Arteries; Deferoxamine; Disease Models, Animal; Female; Ischemic Attack, Transient; | 1996 |
Effects of deferoxamine and sympathectomy on endothelin-1-induced contraction and acetylcholine-induced relaxation following subarachnoid hemorrhage in carotid artery.
Topics: Acetylcholine; Animals; Carotid Artery Diseases; Carotid Artery, Common; Deferoxamine; Endothelin-1; | 1997 |
Evaluation of cerebral vasospasm with transcranial magnetic stimulation: an experimental study.
Topics: Animals; Basilar Artery; Blood Pressure; Capillaries; Cerebral Angiography; Deferoxamine; Evoked Pot | 2001 |
Inhibition of delayed arterial narrowing by the iron-chelating agent deferoxamine.
Topics: Animals; Deferoxamine; Free Radicals; In Vitro Techniques; Iron; Ischemic Attack, Transient; Lipid P | 1992 |
A study of the effectiveness of the iron-chelating agent deferoxamine as vasospasm prophylaxis in a rabbit model of subarachnoid hemorrhage.
Topics: Animals; Basilar Artery; Brain; Deferoxamine; Disease Models, Animal; Iron Chelating Agents; Ischemi | 1991 |